[{"uuid": "45bccb20-268d-3075-a01b-a9521d2dfc3a", "title": "BMY Gets Positive CHMP Opinion for Opdivo, Yervoy Combo and Breyanzi", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/bmy-gets-positive-chmp-opinion-183400618.html", "providerPublishTime": 1738607640, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/SlGE5JR4xp73Vb5zTu29cQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/iAjYTqhtpV3hPzryhmSe_g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/52b6d392b63705aefb517365eab38a95", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CELG-RT"]}, {"uuid": "f263b529-df2c-3330-a342-dc758b821dd5", "title": "Exploring High Growth Tech Stocks in February 2025", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/exploring-high-growth-tech-stocks-180341911.html", "providerPublishTime": 1738605821, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/._HFmWFPcwt6muyT_tZE7g--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/j83YAAY5dC9mBeTXDOIrRw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/b394072c431426666ba19d9f9857f297", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL", "AAOI", "GLOB"]}, {"uuid": "5450f6dd-dd9f-37cc-b110-bc4a818a10c2", "title": "EXEL Industries: First quarter 2024\u20132025 sales down 19.0%", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/exel-industries-first-quarter-2024-070400985.html", "providerPublishTime": 1738047840, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/1xDgOx.BPOHgU27sxWkgTA--~B/aD0yMzg4O3c9NDQ1NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/ef93e2319f8597be8fae681c05c7d025", "width": 4457, "height": 2388, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/kcoH3L.YkwkbBNqjAixyTw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/ef93e2319f8597be8fae681c05c7d025", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXE.PA"]}, {"uuid": "a743c7d7-a2aa-380a-86e2-3c2a3472fd01", "title": "Exelixis (EXEL) Earnings Expected to Grow: Should You Buy?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/exelixis-exel-earnings-expected-grow-150053248.html", "providerPublishTime": 1738076453, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/eeFsK50..hTdRBoBNDEyoA--~B/aD03MTE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b", "width": 900, "height": 711, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/U.GeD2pq81ETtKFpwtAvMA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d2f7ed3d1940141716bfd200f5c94c6b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "17d421b7-bbc3-3798-b48b-3e34bfa2ce87", "title": "Here's Why Exelixis (EXEL) is a Strong Value Stock", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/heres-why-exelixis-exel-strong-144012891.html", "providerPublishTime": 1738161612, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/xMhOxlfdhVA7Ts3pP3IHyA--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83", "width": 900, "height": 633, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1wWgvR9AXA1o_EfTypadHw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "1d855811-8ae0-3fd7-9da6-9afff75c49dc", "title": "Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/amgen-set-report-q4-earnings-161000994.html", "providerPublishTime": 1738167000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/._mAv70PW7IAFz5cM1Tjpg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pvIyyMXLKwAjR2pqQ29s0Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMGN"]}, {"uuid": "709ecc59-84d0-3644-a69f-9c997a8e1fe7", "title": "Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/repligen-rgen-surges-3-7-081900136.html", "providerPublishTime": 1738138740, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/MRhreSGbqJgLxGFiqG5lYA--~B/aD01NDc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bfb729ad18029ec52fb0f5cb267f48bd", "width": 900, "height": 547, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/O5aZFnWVW0TjI0Y8YK9ijg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/bfb729ad18029ec52fb0f5cb267f48bd", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["RGEN", "EXEL"]}, {"uuid": "e1ab1ccc-50a8-30ff-a260-6f95c5b96bb8", "title": "Exelixis Stock Falls as Oppenheimer Downgrades Rating to Perform", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/exelixis-stock-falls-oppenheimer-downgrades-173600222.html", "providerPublishTime": 1737999360, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/QieiOVP5CdM1cfxTnlcVfQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795", "width": 620, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1hcqAcr._xcksqqDo_WNwA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/e797ee31d4bee954c41ecfac218dc795", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "5659a655-6bb5-3b5d-a5bb-40804166cfe9", "title": "Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exelixis-release-fourth-quarter-full-210500978.html", "providerPublishTime": 1738098300, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/Wv9ZPHI4e8skc81JUqO9pg--~B/aD0zMjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2012c64eceed4cdb7938c65187d21067", "width": 1200, "height": 327, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/gX0ERgxBljfDABlxHePX4A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2012c64eceed4cdb7938c65187d21067", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "7673c16c-aeb2-3f3c-8bc8-89b8cba162b2", "title": "Exelixis' Revenue Growth Likely to Be Meaningfully Ahead of Consensus, Morgan Stanley Says", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/exelixis-apos-revenue-growth-likely-161855301.html", "providerPublishTime": 1737994735, "type": "STORY"}, {"uuid": "5d42e86b-7c5e-3aab-bcf4-b41beac400b7", "title": "Novartis to Report Q4 Earnings: What's in the Offing?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/novartis-report-q4-earnings-whats-183800470.html", "providerPublishTime": 1738089480, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/1GILAZNg_sZU4tvhUip3sw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/yDFbSqgx8Di1WnwdhMZtig--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["NVS"]}, {"uuid": "b2693a98-161a-3261-8695-5a860e4d5cae", "title": "Truist Lifts Price Target on Exelixis to $43 From $42, Keeps Buy Rating", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/truist-lifts-price-target-exelixis-123353966.html", "providerPublishTime": 1737981233, "type": "STORY", "relatedTickers": ["EXEL"]}, {"uuid": "90cc1285-c774-3e5a-90cb-aab36668747c", "title": "Morgan Stanley Upgrades Exelixis to Overweight From Equalweight, Raises Price Target to $40 From $30", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/morgan-stanley-upgrades-exelixis-overweight-111922627.html", "providerPublishTime": 1737976762, "type": "STORY", "relatedTickers": ["EXEL"]}, {"uuid": "0322a62f-9d09-334e-b3df-b798f115c193", "title": "Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exelixis-announces-encouraging-results-phase-150000798.html", "providerPublishTime": 1737817200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/wcd_qxnjTE4fcg.jRem2Hw--~B/aD0zMjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1ed4b4219ced8749e1ca8f46e27fb2dc", "width": 1200, "height": 327, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/PtEmZjjttq67hsrFmIeolg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/1ed4b4219ced8749e1ca8f46e27fb2dc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "1a597760-c9c6-3f75-9915-b0d307d8dab1", "title": "Exelixis Reports Results on Drug Study to Treat Advanced Gastrointestinal Neuroendocrine Tumors", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/exelixis-reports-results-drug-study-204239755.html", "providerPublishTime": 1737751359, "type": "STORY", "relatedTickers": ["EXEL"]}, {"uuid": "cf52bd56-bf6a-3e52-b202-19cf9db362f0", "title": "Exelixis Shares Fall After Downgrade From Oppenheimer", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/exelixis-shares-fall-downgrade-oppenheimer-193209284.html", "providerPublishTime": 1737747129, "type": "STORY"}, {"uuid": "8ddadb5a-003d-3aaf-bf08-c4709afbde72", "title": "Oppenheimer Downgrades Exelixis to Perform From Outperform, Adjusts Price Target to $33 From $41", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/oppenheimer-downgrades-exelixis-perform-outperform-131335726.html", "providerPublishTime": 1737724415, "type": "STORY", "relatedTickers": ["EXEL"]}, {"uuid": "4fd10a7d-6de7-3f09-87f6-fdb8d4a47f28", "title": "Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/exelixis-announces-results-subgroup-analysis-193000830.html", "providerPublishTime": 1737747000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/WsymuGWG5aVqSmQNT2pRvQ--~B/aD0zMjc7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/66f496e69027644d1d25c4c0f922d8f2", "width": 1200, "height": 327, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/DXAZGikX6koGVsUB1Z3BhQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/66f496e69027644d1d25c4c0f922d8f2", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "47c39b22-a078-383e-bbe8-9baa7cce5514", "title": "EXEL vs. TECH: Which Stock Is the Better Value Option?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/exel-vs-tech-stock-better-164010487.html", "providerPublishTime": 1737477610, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CorpxfcSD3xaruoFanouDg--~B/aD00NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a", "width": 900, "height": 476, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pdW5wHTIEKqiEK3RrmtVaw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/ace7df31c7fcb10255abe7c990ea373a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}, {"uuid": "540a38bf-3f13-3fa7-83b7-f565a4fa92d9", "title": "Exelixis Stock Faces a Reality Check: Will It Hit $41 or Drop to $33?", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/exelixis-stock-faces-reality-check-183712226.html", "providerPublishTime": 1737743832, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/nheCcqYGj.KWAZQ9xbtWfw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/15f98b213e646805ad1d06ee9a7ace3b", "width": 400, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/1c6zzHrbC6_gZ1UnIwZitg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/15f98b213e646805ad1d06ee9a7ace3b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["EXEL"]}]